Company / Cash & Equivalents
Taysha Gene Therapies, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$319.8M
FY2025
5-year range
$87.9M / $319.8M
FY2021-FY2025
Trend
+130.0%
vs FY2024
Sector context
#61 of 207
Health Care
What the data says
At $320M, Taysha Gene Therapies, Inc.'s cash & equivalents ranks #61 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 6 years, ranging from $88M in FY2022 to $320M in FY2025.
Based on SEC 10-K filings.
$320M in FY2025 with a 5-year CAGR of +4.9%.
Improved from $144M to $320M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +53.8%
- 5-Year CAGR
- +4.9%
- 10-Year CAGR
- -
Sector benchmark
#61 of 207 in Health CareTop 29% of 207This company $319.8M Sector average $669.5M
▼
-52.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 130.0% year-over-year.
- Ranks #61 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $319.8M | +130.0% |
| FY2024 | $139.0M | -3.4% |
| FY2023 | $143.9M | +63.8% |
| FY2022 | $87.9M | -41.1% |
| FY2021 | $149.1M | -40.7% |
| FY2020 | $251.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026